NBS superfood: a promising adjunctive therapy in critically ill ICU patients with omicron variant of COVID-19

AMB Express

Table 2 Comparison of the variables in both control and intervention groups at both the baseline and the 14-day post-intervention

Variables	Groups	N	Mean	Std. deviation	Std. error mean	P-value
Group statistics
CRP (baseline)	Intervention	200	40.80	27.97	1.98	0.227^a
CRP (baseline)	Control	200	37.64	24.18	1.71	0.227^a
CRP (after intervention)	Intervention	200	15.39	11.55	0.82	0.000^a
CRP (after intervention)	Control	200	48.49	32.60	2.31	0.000^a
ESR (baseline)	Intervention	200	26.46	15.30	1.08	0.332^a
ESR (baseline)	Control	200	28.00	16.52	1.17	0.332^a
ESR (after intervention)	Intervention	200	14.28	8.10	0.57	0.000^a
ESR (after intervention)	Control	200	34.03	16.08	1.14	0.000^a
D-Dimer (baseline)	Intervention	200	807.80	438.70	31.02	0.305^a
D-Dimer (baseline)	Control	200	759.26	503.92	35.63	0.305^a
D-Dimer (after intervention)	Intervention	200	485.18	279.06	19.73	0.000^a
D-Dimer (after intervention)	Control	200	1009.13	699.12	49.44	0.000^a
CPK. (baseline)	Intervention	200	100.12	84.44	5.97	0.748^a
CPK. (baseline)	Control	200	97.46	81.18	5.74	0.748^a
CPK (after intervention)	Intervention	200	68.93	57.36	4.06	0.000^a
CPK (after intervention)	Control	200	131.48	102.95	7.28	0.000^a
Lymphocyte (baseline)	Intervention	200	1135.54	362.61	25.64	0.055^a
Lymphocyte (baseline)	Control	200	1206.38	374.84	26.50	0.055^a
Lymphocyte (after intervention)	Intervention	200	1537.06	469.04	33.17	0.000^a
Lymphocyte (after intervention)	Control	200	1152.60	551.33	38.98	0.000^a

C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), D-Dimer (a fibrin degradation product), Creatine Phosphokinase (CPK), N: number of samples
^aIndependent samples t-test